Tinengotinib with standard treatments for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called tinengotinib combined with standard treatments for men with advanced prostate cancer that has stopped responding to abiraterone or enzalutamide. The goal is to see if the combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are currently taking the full dose of either abiraterone or enzalutamide, and your cancer has started growing again despite this treatment
- Your cancer has spread to at least 2 spots on your bones, or to soft tissue (like lymph nodes or organs) as seen on a CT or MRI
- You have either a tumor that can be measured on a scan, or a PSA level of 2.0 or higher
- You have had your testosterone lowered by medication or surgery for at least 90 days
- You are willing to have a tumor biopsy if safe and possible (unless you have had a recent biopsy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests two drugs—talazoparib and enzalutamide—given together to men whose metastatic prostate cancer has worsened after treatment with abiraterone (Zytiga). The goal is to see if this combination can help control the cancer.
This study tests a new drug called zanzalitinib in men whose prostate cancer has spread and stopped responding to standard hormone treatments. The drug works differently than previous treatments and may help slow or shrink the cancer.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.